This message was sent to ##Email##
|
|
|
|
|
| |
ACS-NCDB
The National Cancer Database (NCDB) announces that the Participant User File (PUF) application is now open. The NCDB is accepting applications for site-specific files, which include cases diagnosed between 2004 and 2015, through Sept. 18. For more information, review the PUF website. Questions regarding the NCDB PUF or the RFA process for a PUF may be directed to NCDB technical staff at NCDB_PUF@facs.org.
ACS
Hospitals are not off limits to tragic shooting events, and with these incidents on the rise in public places, more than half of the general public expects that physicians and nurses will protect them from harm if an active shooter event erupts while they're in the hospital. Likewise, more than half of health care professionals believe they have a special duty to protect patients under these circumstances. But the two groups differ about the inherent safety of hospitals, with most people viewing them as safe havens, while health care professionals are more likely to view the hospital as a potentially risky setting for an active shooter event. These beliefs are among key findings from a national survey conducted in March 2017 by the Hartford Consensus. The results are published online as an "article in press" on the website of the Journal of the American College of Surgeons in advance of print.
READ MORE
ACS-Cancer Programs
Reserve your hotel by Aug. 17 to secure the special conference rate of $175 per night. Click here for hotel information.
Don't miss the Big Data Revolution general session moderated by David P. Winchester, MD, FACS, where well-known experts will address:
- Applications of Big Data in Evidence‐Based Medicine—Carolyn Compton, MD, PhD, FCAP
- Biden Cancer Initiative—Deborah Mayer, PhD, RN, AOCN, FAAN
- National Minority Quality Forum—Gary Puckrein, PhD
This and many other topics will be addressed at the 2017 Cancer Programs Conference: Creating a Culture of Quality.
Need help securing funding to attend the 2017 Cancer Programs Conference? Use the Justification Toolkit.
|
Promoted by
|
|
|
|
 |
Oncology Nurse Advisor
The number of people with cancer diagnosed at age 85 years or older — so-called super-elders — is increasing sharply, posing challenges for radiation oncology planning. Geriatric oncology evaluations and careful communication to identify patients' goals and priorities for care will play important roles in personalizing treatment plans.
READ MORE
ACS
The American College of Surgeons Cancer Programs will kick off the 2017 Cancer Programs Conference: Creating a Culture of Quality, Sept. 8–9 in Chicago. In conjunction with the conference, surgeon advocates from across the nation will be able to participate in the ACS Cancer Programs' 2017 Virtual Capitol Hill Day Sept. 8. Aimed at protecting the future of quality cancer care through advocacy, the Cancer Programs' first Virtual Capitol Hill Day will give College members and the consortium of professional organizations dedicated to cancer patients and their care an opportunity to make their voices heard in the halls of Congress via social media. With additional resources provided by the ACS Division of Advocacy and Health Policy staff, advocates will be able to leverage the ACS Cancer Programs' message, engage elected officials and share stories regarding how these issues affect their practices and their patients' lives.
For more information, contact Carrie Zlatos, ACS Senior Congressional Lobbyist, at czlatos@facs.org or Katie Oehmen, Manager of ACSPA-SurgeonsPAC and Grassroots, at koehmen@facs.org.
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
Enjoy our journals? There’s an app for those! Journals such as those from the American Cancer Society ™, Journal of Surgical Oncology, Cancer Science and more are now available for your iPad and iPhone. Sample issues and abstracts, as well as open articles, can be accessed for free. A subscription to the journal is required to read the full text. Click here to learn more!
|
|
Medscape
In frail patients with cancer who are to undergo contrast-enhanced CT, the choice of iodated contrast medium can be key to reducing risk for impaired renal function and the development of contrast-induced nephropathy (CIN).
In a head-to-head comparison of two contrast media, iodixanol (Visipaque, GE Healthcare) appeared to have a better safety profile than iopromide (Ultravist, Bayer Healthcare). The results come from the blinded, randomized COMEDIANS trial, which was conducted in 504 cancer patients at low risk for CIN who underwent chest-abdomen-pelvic CT.
READ MORE
ACS-CRP
The deadline for the 2017 Commission on Cancer (CoC) Prostate Special Study to investigate follow-up and recurrence after prostate cancer treatment is Monday, Aug. 28. As previously communicated, participation in this Special Study is required by all CoC-accredited sites to fulfill Standard 5.7 (with few exceptions that have already been communicated). The last day to receive a replacement patient is Monday, Aug. 21, so it is critical to determine eligibility of the patients as soon as possible. All eligible records must be completed and submitted by the deadline in order to receive a rating of Compliance for Standard 5.7. Sites failing to complete data collection for all eligible patients by the deadline will receive a rating of Noncompliance for Standard 5.7. If you have any additional questions, email specialstudy@facs.org.
 |
|
Novodiax is soon bringing to market 10-minute fast, sensitive and simple Immunoassay (IHC) kits for in vitro diagnostic use to address unmet needs in the intraoperative surgical oncology sector. Learn More
|
|
Medical Xpress
Sanford Health is the first site in the United States to launch a clinical trial using a genetically engineered virus that aims to destroy therapy-resistant tumors. The Phase I immunotherapy trial is for patients ages 18 and older with metastatic solid tumors who have not responded to standard treatments. The treatment injects an oncolytic (cancer-destroying) virus—vesicular stomatitis virus (VSV)—into the tumor. The virus is engineered to grow in cancer cells, destroy these tumors and then spread to other cancer sites. During this process, it recruits the immune system to the area with the goal of triggering an immune response.
READ MORE
ScienceDaily
Being able to predict the resistance or sensitivity of a tumor cell to a drug is a key success-factor of cancer precision therapy. But such a prediction is made difficult by the fact that genetic alterations in tumors change dynamically over time and are often interdependent, following a pattern that is poorly understood. A recent study led by researchers at the SIB Swiss Institute of Bioinformatics, University of Lausanne and EPFL provides a promising framework to anticipate drug resistance in cancer by predicting the co-occurrence of about 500 known tumor alterations, as well as their response to more than 200 common cancer drugs.
READ MORE
|
Promoted by
|
|
|
|
 |
George Washington University
Don't miss your chance to apply for the George Washington University (GW) Cancer Center's Together-Equitable-Accessible-Meaningful (TEAM) training! This no-cost training for health care organizations that provide cancer-related services aims to improve the productivity of patient-provider interactions to promote equitable, accessible and patient-centered cancer care. The multi-phase training program includes a self-paced online course, a two-day workshop in Washington, D.C., and technical assistance from nationally renowned faculty in creating and implementing a quality improvement plan. Looking to share more information about the TEAM training with your networks? We've got you covered.
Reuters
Patients with cancer have higher risks of heart attack and stroke from blood clots, especially in the first few months after diagnosis, compared with people who don't have cancer, researchers report.
"A new diagnosis of cancer is associated with more than a doubling in risk of stroke and heart attack in the first six months after cancer diagnosis," Dr. Babak B. Navi from Weill Cornell Medicine in New York City told Reuters Health by email. "Therefore, cancer patients and their doctors need to pay more attention to the potential secondary complications of cancer and its treatments, particularly the cardiovascular ones, which are associated with substantial morbidity and mortality."
READ MORE
 |
|
Doctors Without Borders/Médecins Sans Frontières (MSF) is actively recruiting general and trauma surgeons with experience in emergency obstetrics for international missions in developing countries. Learn more.
|
|
Medical Xpress
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research led by Nada Kalaany, PhD, at Boston Children's Hospital and the Broad Institute of MIT and Harvard, now suggests a novel approach to treating this deadly cancer: targeting an enzyme that tumors use to get rid of nitrogen.
READ MORE
Oncology Nurse Advisor
Colorectal cancer (CRC) mortality rates have decreased since 1970 in black adults (aged 20 to 54 years) but increased among white individuals, according to a research letter published in the Aug. 8 issue of the Journal of the American Medical Association. Rebecca L. Siegel, M.P.H., from the American Cancer Society in Atlanta, and colleagues obtained data from SEER*Stat for decedents aged 20 to 54 years as reported by the National Center for Health Statistics to examine CRC mortality from 1970 to 2014.
READ MORE
ACS
Registration is now open for the American College of Surgeons Clinical Congress 2017, Oct. 22–26 in San Diego. Clinical Congress is one of the largest meetings of surgeons in the world and offers outstanding educational opportunities for every stage of your career. The theme of this year's conference is Do What's Right for the Patient.
READ MORE
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The CoC and NAPBC do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons, the CoC and the NAPBC.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
